Updated:
STERIS
STERIS was founded in 1985 as Innovative Medical Technologies and rebranded after a 1987 merger.
STERIS
STERIS was founded in 1985 as Innovative Medical Technologies and rebranded after a 1987 merger. Dan Carestio took over as CEO in 2016, inheriting a company that had already spent two decades consolidating the fragmented market for infection-prevention products and services. The firm's legal seat moved to Dublin in 2019 following the acquisition of Cantel Medical, aligning its tax structure with an increasingly global revenue base. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Healthcare sells capital equipment — surgical tables, washer-disinfectors, steam sterilizers — plus the service contracts and consumables that generate roughly 70% of recurring revenue. Applied Sterilization Technologies runs a network of contract sterilization facilities that process single-use medical devices for OEMs, using ethylene oxide, gamma, and electron beam modalities. Life Sciences supplies cleanroom consumables and barrier isolators to pharmaceutical manufacturers. Acquisitions define the growth playbook — Cantel Medical in 2021 for $4.6B added endoscopy reprocessing and dental consumables; the 2024 purchase of Surgical Notes expanded revenue-cycle management capabilities (per the firm's official communications, 2024). STERIS employs roughly 18,000 people across manufacturing sites in North America, Europe, and Asia. The company reports annual revenue exceeding $5B. A 2024 restructuring into three geographic regions — Americas, Europe/Middle East/Africa, and Asia Pacific — signaled an intention to drive operational accountability closer to local markets. The firm maintains a dedicated applied research team that collaborates with Mayo Clinic and other academic medical centers on sterilization-validation protocols. Unlike medical-device OEMs that rely on in-house sterilization, STERIS aggregates demand across thousands of hospital systems and device makers, funding the specialized infrastructure — ethylene oxide chambers and gamma irradiators — that no single customer would build alone. That shared-utility model means contract renewal rates stay above 95%, because switching to a rival or insourcing requires regulatory revalidation that takes 12–18 months.
General information
Firm type
other
Year founded
1985
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mentor
Corporate office
Mentor, OH, United States
Additional offices
Dublin, Ireland
Principals
Dan Carestio
President and CEO
Sector focus
Frequently asked questions
What are STERIS's primary revenue segments?
STERIS reports through three segments: Healthcare (surgical capital equipment, service, and consumables), Applied Sterilization Technologies (contract sterilization for medical-device OEMs), and Life Sciences (cleanroom products for pharma). Healthcare is the largest, and within it, consumables and service contracts generate the majority of recurring revenue, insulating the business from capital-spending cycles at hospitals.
How does STERIS's contract sterilization business create a competitive moat?
The Applied Sterilization Technologies segment operates ethylene oxide and gamma irradiation facilities that single-use device manufacturers rely on for FDA-cleared sterilization. Switching providers requires revalidating entire production lines with regulators, a process that often takes over a year. Because STERIS provides capacity that would be uneconomical for any single OEM to replicate, contract renewal rates remain exceptionally high.
Why did STERIS move its legal domicile to Ireland?
STERIS redomiciled to Dublin in 2019 as part of its acquisition of Cantel Medical, a US-based infection-prevention company, through a UK-scheme-of-arrangement structure. The move aligned the corporate tax residence with an increasingly international revenue profile and has remained in place post-acquisition, with operational headquarters still anchored in Mentor, Ohio.
What role do acquisitions play in STERIS's growth strategy?
Acquisitions are central. The $4.6B Cantel Medical deal in 2021 added endoscopy reprocessing and dental infection-control lines; the 2024 purchase of Surgical Notes pushed the company into revenue-cycle management software for surgery centers. STERIS targets fragmented adjacent markets where its existing hospital relationships can accelerate product distribution.
Is STERIS a medical-device manufacturer or a service provider?
It is both. The company designs and sells capital equipment — sterilizers, surgical tables, washer-disinfectors — but the larger economic engine is recurring: service contracts on that installed base, plus the consumables (sterilization wraps, detergents, biological indicators) that hospitals reorder continuously. The contract sterilization division functions as a pure outsourced service.
How exposed is STERIS to hospital capital-budget cycles?
Partially, but the business model is structured to dampen volatility. Capital equipment represents a minority of revenue; roughly 70% comes from recurring consumables, service contracts, and outsourced sterilization fees. Even when hospitals defer new sterilizer purchases, they must keep existing units maintained and continue buying the proprietary chemistries those units consume.
Who leads operations and strategic direction at STERIS?
Dan Carestio has served as President and CEO since 2016, succeeding Walter Rosebrough, who led the company through its 2005–2015 acquisition spree. Carestio previously ran the Healthcare and Life Sciences segments. The senior leadership team is concentrated in Mentor, Ohio, with regional presidents managing the Americas, EMEA, and Asia Pacific since the 2024 restructuring.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: